Malaria vaccine wears off Setback to experimental vaccine
Eastern Eye Staff
AN EXPERIMENTAL vaccine against malaria known as Mosquirix – or RTS,S – weakens over time and is only four per cent effective over a seven-year span, researchers said last Wednesday (29). The findings, published in the New England Journal of Medicine, are based on a phase II clinical trial with over 400 young children in Kenya. There is currently no vaccine against malaria on the world market and Mosquirix – developed by the British pharmaceutical giant Glaxo Smith-Kline – is the experimental vaccine in the most advanced stage of development. It has also been tested in a vast clinical trial…
You do not have access to this content. You need to subscribe.